Roger Anton Fredy Von Moos, Andreas Müller, Stefanie Hayoz, Michael Thomas Mark, Stefanie Fischer, Razvan Andrei Popescu, Sacha I. Rothschild, Mathias Konrad Fehr, Claudine Egger, Sandro Anchisi, Florian Schmid, Khalil Zaman, Christoph Jakob Ackermann, Hubert Kugler, Priska Bützberger, Catrina Uhlmann, Marc Küng, Simone Wyss, Arnoud J. Templeton, Silke Gillessen. "Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1004